IDH1, isocitrate dehydrogenase (NADP(+)) 1, 3417

N. diseases: 399; N. variants: 10
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE Brusatol selectively suppressed IDH1-mutated cancer progression in vivo (mean [SD] final tumor volume was 761.6 [391.6] mm3 in the control and 246.2 [215] mm3 in the brusatol-treated group, P = .02). 30759236 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE We hypothesize that the primary cell pool isolated from LGG tumor contains a heterogeneous population consisting tumor cells at various stages of tumor progression including cells with early genetic lesions if any prior to acquisition of IDH1 mutation. 30460631 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE These <i>IDH1/2</i> mutations are thought to result in hypermethylated histones and DNA which in turn alters gene expression and drives cancer progression. 30405699 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 AlteredExpression phenotype BEFREE In conclusion, wild-type IDH1 is over-expressed in lung adenocarcinoma which probably promoted tumor progression via increasing CSCs survival. 29537891 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE Data from a preclinical study suggest rethinking the "oncometabolite hypothesis," which calls for blocking the product of neomorphic <i>IDH1/2</i> mutations to halt tumor progression. 28381406 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE Radiomic models using automated texture analysis and VASARI features were built to predict isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q codeletion status, histological grade, and tumor progression. 28339588 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE It is plausible that the NRF2 pathway plays an important role in tumor progression of anaplastic gliomas with IDH1/2 mutations. 25304134 2015
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE Here, we identify 2 gliomas that underwent loss of the wild-type IDH1 allele but retained the mutant IDH1 allele following tumor progression from World Health Organization (WHO) grade III anaplastic astrocytomas to WHO grade IV glioblastomas. 23204232 2013
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.090 GeneticVariation phenotype BEFREE Our data suggest that IDH1 or IDH2 mutation plays a role in early tumor progression of several types of glioma and might arise from a common glial precursor. 19765000 2009